Edition:
India

Luye Pharma says Innovative Drug Risperidone Extended Release Microspheres For Injection Reaches Final Stage Of NDA Process


Monday, 31 Dec 2018 

Dec 30 (Reuters) - Luye Pharma Group Ltd <2186.HK>::LUYE PHARMA GROUP ANNOUNCES INNOVATIVE DRUG RISPERIDONE EXTENDED RELEASE MICROSPHERES FOR INJECTION HAS REACHED FINAL STAGE OF NDA PROCESS.SUCCESSFULLY REACHED AN AGREEMENT WITH FDA TO WAIVE ALL PAEDIATRIC CLINICAL STUDIES OF LY03004.OBTAINED FDA'S APPROVAL OF USING RYKINDO AS LY03004'S BRAND NAME FOR TREATMENT OF SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER. 

Company Quote

6.18
-0.07 -1.12%
20 Sep 2019